Xinnuo Meidi

Company Profile: Beijing Xinnuo Meidi Gene Testing Technology Co., Ltd. was founded in 2008 and is a pioneer in the domestic molecular diagnostics field. The company is committed to providing high-quality products and comprehensive services to clinical practice. It has established four core technology platforms: PCR, sequencing, FISH, and NGS. On this basis, it has developed business segments such as liquid biopsy for tumors, individualized tumor testing, pharmacogenomics, and pathogenic microorganisms. Its landmark products include a series of tests for early tumor screening, individualized tumor drug testing, tumor drug resistance monitoring, cardiovascular drug testing, and immune testing. Product Strength: Xinnuo is dedicated to developing Class III medical device gene diagnostic products that meet clinical needs, and on this basis has formed the core technologies AMRS-PLUS and XmAmpli, completing a full-cycle tumor testing product series. It constantly focuses on technological advancement and product quality control to provide customers with gene diagnostic products that meet clinical performance requirements. The company has obtained 22 product certificates issued by the China Food and Drug Administration (CFDA), with another 5 products accepted, and more than 100 other products under development or completed, covering multiple fields such as early tumor screening, tumor individualization, pharmacogenomics, and pathogenic microorganisms. It has established business relationships and conducted in-depth cooperation with more than 260 large tertiary hospitals nationwide. Industry Position: A pioneer in the development and market of precision tumor diagnostic products, committed to exploring the clinical application of gene diagnostics. Development Direction: The company has long focused on full-cycle tumor testing, including early screening, individualized medication guidance, prognostic testing, and drug resistance monitoring. It will continue to develop clinically meaningful Class III gene testing products around tumors and create a series of products to guide clinical medication for tumor patients. R&D Capability: Xinnuo Meidi's R&D center is a Beijing municipal-level enterprise science and technology research and development center. The R&D team continuously follows the latest basic research progress and develops clinically meaningful gene diagnostic products; it undertakes multiple provincial and ministerial-level projects, conducts basic research, and actively carries out achievement transformation to develop forward-looking cancer screening products.